Page 144 - Acrobat J Trad-21-3-2566

J Thai Trad Alt Med Vol. 21 No. 3 Sep-Dec 2023 627

Table 2 Inhibitory activity of Kratom extracts on alpha-glucosidase and alpha-amylase enzymes.

Inhibitory activity (IC 50; µg/mL)
Kratom Extracts
alpha-amylase alpha-glucosidase

KE95 > 1000* > 1000*
KE70 > 1000* 382.64 ± 16.18*
KE50 > 1000* 409.43 ± 19.14*
KDec > 1000* > 1000*
Acarbose 7.43 ± 0.71 115.96 ± 15.20
*Significant difference from the positive control, Acarbose, analyzing by one-way ANOVA with Dunnett’s test.

2. In vitro inhibitory effect on angioten- ited the inhibition level of nearly 50% (data not
sin-I converting enzyme (ACE) shown). Consequently, KDec was later evalu-

The inhibitory activity of Kratom extracts ated to determine its IC 50 value. However, the
on ACE was investigated to determine their IC 50 value of KDec was found to be 1056.08 ±

potential as an anti-hypertensive medicine. 3.4 µg/mL. Captopril was utilized as a posi-
The extracts were screened at a concentration tive control and demonstrated potent effects
of 1,000 µg/mL. All extract demonstrated the with an IC 50 value of 0.007 ± 0.0004 µg/mL

%inhibition significantly less than 50%, except (Table 3).
for the aqueous extract (KDec), which exhib-

Table 3 Inhibitory activity of Kratom extracts on angiotensin-I converting enzyme (ACE).

Kratom Extract Inhibitory activity (IC 50; µg/mL)
KE95 > 1000*
KE70 > 1000*
KE50 > 1000*
KDec 1051.19 ± 8.80*
Captopril 0.007 ± 0.0004

* Significant difference from the positive control, Captopril, analyzing by one-way ANOVA with Dunnett’s test.